The Children’s Hospital of Pittsburgh of UPMC joined other prominent U.S. centers taking part in the Xplore-2 clinical trial. The medical institutions that may enroll patients in the Xplore-2 Early Feasibility Study include: Boston Children’s Hospital, Children’s Healthcare of Atlanta, Children’s Hospital of Los Angeles, Children’s Hospital of Philadelphia and New York Presbyterian/Columbia University Medical Center.
Xplore-2 is an FDA-approved Early Feasibility Study evaluating Xeltis’ novel restorative pulmonary heart valve for Right Ventricular Outflow Tract (RVOT) reconstruction. Xeltis’ restorative pulmonary valve is an investigational device not approved for use in the United States.
Every year in the USA, approximately 40,000 children are born with congenital heart disease (CHD). Around 15-20 percent of these children have congenital defects of the RVOT. Defective RVOTs require surgical intervention, which often involves replacement of the pulmonary valve.
The Children’s Hospital of Pittsburgh of UPMC is ranked in several elite lists of pediatric hospitals and is one of 10 pediatric hospitals in the USA named to the U.S. News & World Report Honor Roll of America’s “Best Children’s Hospitals” for 2017-2018.
For more information on the Xplore2 clinical trial visit: xplore2trial.com
For more information on current and upcoming treatment options for RVOT reconstruction view the Mended Little Hearts webinar: http://bit.ly/2p79nQV